NCT00406471View on ClinicalTrials.gov

Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Ischemic Central Retinal Vein Occlusion
Interventions
DRUG

Ranibizumab (Lucentis)

500 microgram intravitreal injection for 8 months or 300 microgram intravitreal injection for 8 months

Trial Locations (1)

77030

Vitreoretinal Consultants, Houston

All Listed Sponsors
lead

Greater Houston Retina Research

OTHER

NCT00406471 - Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion | Biotech Hunter | Biotech Hunter